18F-FDG-PET-CT in soft tissue sarcomas: When to imageα;18F-FDG-PET-TC en sarcomas de partes blandas: ¿cuándoα

Revista Espanola de Medicina Nuclear e Imagen Molecular

Volumn 33, Issue 1, 2014, Pages 43-49

  Rodriguez Alfonso B ^a   Mucientes Rasilla, J ^a   Mitjavila Casanovas, M ^a   Cardona Arbonies J ^a   Cubedo, R ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; SOFT TISSUE SARCOMA; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; HUMAN; MULTIMODAL IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; SARCOMA; SCINTISCANNING; SECONDARY; SOFT TISSUE TUMOR; TUMOR RECURRENCE;

FLUORODEOXYGLUCOSE F18; HUMANS; MULTIMODAL IMAGING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SARCOMA; SOFT TISSUE NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84893007540     PISSN: 2253654X     EISSN: 22538070     Source Type: Journal    
DOI: 10.1016/j.remn.2013.07.005     Document Type: Article

References (43)

1. Garcia del Muro X. Sociedad Española de Oncología Médica: Sarcomas de partes landas. Disponible en: [consultado 14 Mar 2013]. http://www.seom.org/es/informacion-sobre-el-cancer/info-tipos-cancer/sarcomas/sarcomas-partes-blandas%3Fstart=1.
2. Ferrís i Tortajada J., Ortega García J.A., López Andreu J.A., García i Castell J., Berbel Tornero O., Llinares Riestra E., et al. Factores de riesgo asociados a sarcomas de partes blandas pediátricos. Rev Esp Pediatr 2001, 57:445-457.
3. Clasificación de los sarcomas de partes blandas de la OMS. Disponible en: [consultado 14 Mar 2013]. http://www.iarc.fr/en/publications/pdfs-online/pat-gen/bb5.
4. Eary J.F., Conrad E.U. Imaging in Sarcoma. J Nucl Med 2011, 52:1903-1913.
5. García del Muro X., Martín J., Maurel J., Cubedo R., Bagué S., de Álava E., et al. Guía de práctica clínica en los sarcomas de partes blandas. Conferencia de Consenso. Med Clin 2011, 136:408. e1-e18.
6. Nanni C., Fanti S. FDG-PET and PET/TC for evaluating soft tissue sarcomas. PET Clinics 2010, 5:341-347.
7. Ioannidis J.P.A., Lau J. 18F-FDG for the Diagnosis and grading of soft-tissue sarcoma: A meta-analysis. J Nucl Med 2003, 44:717-724.
8. Tateishi Yamaguchi U., Seki K., Terauchi T., Arai Y., Hasegawa T. Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: A prospective evaluation by [18F]fluorodeoxyglucose positron emission tomography. Eur J Nucl Med Mol Imaging 2006, 33:683-691.
9. Quak E., van de Luijtgaarden A.C., de Geus-Oei L.F., van der Graaf W.T., Oyen W.J. Clinical applications of positron emission tomography in sarcoma management. Expert Rev Anticancer Ther 2011, 11:195-204.
10. Treglia G., Taralli S., Bertagna F., Salsano M., Muoio B., Novellis P., et al. Usefulness of Whole-Body Fluorine-18-Fluorodeoxyglucose positron emission tomography in patients with neurofibromatosis type 1: A systematic review. Radiol Res Pract 2012, 1-9.
11. Benz M.R., Dry S.M., Eilber F.C., Allen-Auerbach M.S., Tap W.D., Elashoff D., et al. Correlation between glycolytic phenotype and tumor grade in soft-tissue sarcomas by 18F-FDG PET. J Nucl Med 2010, 51:1174-1181.
12. Schwarzbach M.H., Hinz U., Dimitrakopoulou-Strauss A., Willeke F., Cardona S., Mechtersheimer G., et al. Prognostic significance of preoperative [18-F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas. Ann Surg 2005, 241:286-294.
13. Rakheja R., Makis W., Skamene S., Nahal A., Brimo F., Azoulay L., et al. Correlating metabolic activity on 18F-FDG PET/CT with histopathologic characteristics of osseous and soft-tissue sarcomas: A retrospective review of 136 patients. AJR Am J Roentgenol 2012, 198:1409-1416.
14. Nishiyama Y., Tateishi U., Kawai A., Chuman H., Nakatani F., Miyake M., et al. Prediction of treatment outcomes in patients with chest Wall sarcoma: Evaluation with PET/CT. JPN J Clin Oncol 2012, 42:912-918.
15. Eary J.F., O'Sullivan F., O'Sullivan J., Conrad E.U. Spatial heterogeneity in sarcoma 18F-FDG uptake as a predictor of patient outcome. J Nucl Med 2008, 49:1973-1979.
16. Roberge D., Vakilian S., Alabed Y.Z., Turcotte R.E., Freeman C.R., Hickeson M. FDG PET/CT in initial staging of adult soft-tissue sarcoma. Sarcoma 2012, 2012:960194.
17. Jones N.B., Iwenofu H., Scharschmidt T., Kraybill W., Prognostic Factors Staging fos soft tissue sarcomas: An update. Surg Oncol Clin N Am 2012, 21:187-200.
18. Edge S.B., Byrd D.R., Compton C.C., Fritz A.G., Greene F.L., Trott A. AJCC Cancer Staging Manual 2010, Springer. 7th ed.
19. Völker T., Denecke T., Steffen I., Misch D., Schönberger S., Plotkin M., et al. Positron emission tomography for staging of pediatric sarcoma patients: Results of a prospective multicenter trial. J Clin Oncol 2007, 25:5435-5441.
20. Ricard F., Cimarelli S., Deshayes E., Mognetti T., Thiesse P., Giammarile F. Additional Benefit of F-18 FDG PET/CT in the staging and follow-up of pediatric rhabdomyosarcoma. Clin Nucl Med 2011, 36:672-677.
21. FuglØ H.M., Møller Jørgensen S., Loft A., Hovgaard D., Petersen M.M. The diagnostic and prognostic value of 18F-FDG PET/CT in the initial assessment of high-grade bone and soft tissue sarcoma. A retrospective study of 89 patients. Eur J Nucl Med Mol Imaging 2012, 39:1416-1424.
22. Smith R., Demmy T.L. Pulmonary metastatectomy for soft tissue sarcoma. Surg Oncol Clin N Am 2012, 21:269-286.
23. Fortes D.L., Allen M.S., Lowe V.J., Shen K.R., Wigle D.A., Cassivi S.D., et al. The sensitivity of 18F-fluorodeoxyglucose positron emission tomography in the evaluation of metastatic pulmonary nodules. Eur J Cardiothorac Surg 2008, 34:1223-1227.
24. Cook G.J. PET and PET/CT imaging of skeletal metastases. Cancer Imaging 2010, 10:1-8.
25. 18FDG PET, CT, MRI and bone scintigraphy. Eur Radiol 2011, 21:2604-2617.
26. Tateishi U., Yamaguchi U., Seki K., Terauchi T., Arai Y., Kim E.E. Bone and soft-tissue sarcoma: Preoperative staging with fluorine 18 fluorodeoxyglucose PET/CT and conventional imaging. Radiology 2007, 245:839-847.
27. 18F-FDG-PET/CT in initial staging and assessment of early response to chemotherapy of pediatric rhabdomyosarcomas. Nucl Med Commun 2012, 33:1089-1095.
28. Charest M., Hickeson M., Lisbona R., Novales-Diaz J.A., Derbekyan V., Turcotte R.E. FDG PET/CT imaging in primary osseous and soft tissue sarcomas: A retrospective review of 212 cases. Eur J Nucl Med Mol Imaging 2009, 36:1944-1951.
29. Al-Ibraheem A., Buck A.K., Benz M.R., Rudert M., Beer A.J., Mansour A., et al. (18) f-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma. Cancer 2013, 119:1227-1234.
30. Sharma P., Kumar R., Singh H., Jeph S., Sharma J.B., Jain S.K., et al. Role of FDG PET-CT in detecting recurrence in patients with uterine sarcoma: Comparison with conventional imaging. Nucl Med Commun 2012, 33:185-190.
31. Kao Y.H., Saad U., Tan A.E., Magsombol B.M., Padhy A.K. Fluorine-18-fluorodeoxyglucose PET/CT for the evaluation of suspected recurrent uterine leiomyosarcomas. Acta Radiol 2011, 52:463-466.
32. Sung P.L., Chen Y.J., Liu R.S., Shieh H.J., Wang P.H., Yen M.S., et al. Whole-body positron emission tomography with 18F-fluorodeoxyglucose is an effective method to detect extra-pelvic recurrence in uterine sarcomas. Eur J Gynaecol Oncol 2008, 29:246-251.
33. Arush M.W., Israel O., Postovsky S., Militianu D., Meller I., Zaidman I., et al. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma. Pediatr Blood Cancer 2007, 49:901-905.
34. Niccoli-Asabella A., Altini C., Notaristefano A., Merenda N., Altieri M.L., Stabile-Ianora A.A., et al. A retrospective study comparing contrast-enhanced computed tomography with 18F-FDG-PET/CT in the early follow-up of patients with retroperitoneal sarcomas. Nucl Med Commun 2013, 34:32-39.
35. Gaynor J.J., Tan C.C., Casper E.S., Collin C.F., Friedrich C., Shiu M., et al. Refinement of clinicopathologic staging for localized soft tissue sarcoma of the extremity: A study of 423 adults. J Clin Oncol 1992, 10:1317-1329.
36. Evilevitch V., Weber W.A., Tap W.D., Allen-Auerbach M., Chow K., Nelson S.D., et al. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin Cancer Res 2008, 14:715-720.
37. Miki Y., Ngan S., Clark J.C., Akiyama T., Choong P.F. The significance of size change of soft tissue sarcoma during preoperative radiotherapy. Eur J Surg Oncol 2010, 36:678-683.
38. Gupta K., Pawaskar A., Basu S., Rajan M.G., Asopa R.V., Arora B., et al. Potential role of FDG PET imaging in predicting metastatic potential and assessment of therapeutic response to neoadjuvant chemotherapy in ewing sarcoma family of tumors. Clin Nucl Med 2011, 36:973-977.
39. Schwarzbach M.H., Dimitrakopoulou-Strauss A., Willeke F., Hinz U., Strauss L.G., Zhang Y.M., et al. Clinical value of [18-F]] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. Ann Surg 2000, 231:380-386.
40. Eary J.F., Mankoff D.A. Tumor metabolic rates in sarcoma using FDG PET. J Nucl Med 1998, 39:250-254.
41. Schuetze S.M., Rubin B.P., Vernon C., Hawkins D.S., Bruckner J.D., Conrad E.U., et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer 2005, 103:339-348.
42. Tateishi U., Kawai A., Chuman H., Nakatani F., Beppu Y., Seki K., et al. PET/CT allows stratification of responders to neoadjuvant chemotherapy for high-grade sarcoma: A prospective study. Clin Nucl Med 2011, 36:526-532.
43. Hawkins D.S., Schuetze S.M., Butrynski J.E., Rajendran J.G., Vernon C.B., Conrad E.U., et al. [18F]fluorodeoxyglucose positron emission tomography predicts outcome for ewing sarcoma family of tumors. J Clin Oncol 2005, 23:8828-8834.